About Outlook Therapeutics, Inc.
Outlook Therapeutics is a complex clinical-level biopharmaceutical company looking to expand ONS-5010 /LYTENAVA ™ (bevacizumab) as the first FDA-approved bevacizumab ophthalmic formulas for use in retinian indications, adding AMD rainy, DME and BRVO. Bevacizumab is approved, Outlook Therapeutics plans to market it as the first and only FDA-approved bevacizumab ophthalmic formula for use in the treatment of various retinal diseases in the United States, the United Kingdom, Europe, Japan, China and other markets. Therapeutics plans to register the onS-5010 ophthalmic bevacizumab with the US FDA. USA As a new BLA as a component of the PHSA 351 regulatory pathway, first for rainy AMD. For more information, visit www. outlooktherapeutics. com.
Contacts:
Media Requests:
Investor Requests:
Jenene Thomas Ceo Team JTC, LLCT: 833. 475. 8247OTLK@jtcir. com